Viyash ScientificNSE:VIYASH -1.16%76 Return-on-Tangible-Equity is 10.72% as of Mar. 2026, which is 4% above its 10-year median of 10.31. GuruFocus rates NSE:VIYASH with a GF Score™ of 76/100 and a GF Value™ of ₹172.17 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 901 Drug Manufacturers companies, Viyash Scientific ranks better than 64.93% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Viyash Scientific's annualized net income for the quarter that ended in Mar. 2026 was ₹2,084 Mil. Viyash Scientific's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹19,443 Mil. Therefore, Viyash Scientific's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.72%.
The historical rank and industry rank for Viyash Scientific's Return-on-Tangible-Equity or its related term are showing as below:
NSE:VIYASH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -29.1 Med: 10.31 Max: 80.95
Current: 12.7
During the past 13 years, Viyash Scientific's highest Return-on-Tangible-Equity was 80.95%. The lowest was -29.10%. And the median was 10.31%.
NSE:VIYASH's Return-on-Tangible-Equity is ranked better than 64.93% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:VIYASH: 12.70
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Viyash Scientific Return-on-Tangible-Equity Related Terms
Viyash Scientific Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Viyash Scientific's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VIYASH vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viyash Scientific's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viyash Scientific Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viyash Scientific's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Viyash Scientific's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.72% mean?
Viyash Scientific (NSE:VIYASH) has a Return-on-Tangible-Equity of 10.72% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viyash Scientific and its competitors. This is near median its historical median of 10.31. According to the industry distribution chart, Viyash Scientific ranks #316 out of 901 companies in the Drug Manufacturers industry, placing it in the top 35.1%.
Is Viyash Scientific's Return-on-Tangible-Equity too high?
Viyash Scientific's current Return-on-Tangible-Equity of 10.72% is near median its 10-year median of 10.31. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Viyash Scientific's value of 10.72% is 35.7% above this industry median. Based on the distribution chart, Viyash Scientific ranks #316 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viyash Scientific has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viyash Scientific's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Viyash Scientific ranks #316 out of 901 companies for Return-on-Tangible-Equity. This puts Viyash Scientific in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Viyash Scientific's value of 10.72% is 35.7% above this benchmark. While the company's 10-year median is 10.31 vs. the industry median of 7.90, Viyash Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viyash Scientific's current Return-on-Tangible-Equity of 10.72% is 35.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viyash Scientific and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viyash Scientific's current Return-on-Tangible-Equity is 10.72%, which is near median its own 10-year median of 10.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viyash Scientific stock overvalued right now?
Based on GuruFocus' analysis, Viyash Scientific (NSE:VIYASH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹172.17, compared to a current price of ₹277.80 — trading 61.4% above its estimated fair value. The current Return-on-Tangible-Equity is 10.72%, which is near median its 10-year median of 10.31 and 35.7% above the Drug Manufacturers industry median of 7.90. Viyash Scientific's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Viyash Scientific (NSE:VIYASH), the current Return-on-Tangible-Equity is 10.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viyash Scientific (NSE:VIYASH) Overvalued in 2026?
Based on GuruFocus' analysis, Viyash Scientific stock appears to be overvalued.
The current stock price of ₹277.80 is trading 61.4% above its estimated GF Value™ of ₹172.17.
GuruFocus considers Viyash Scientific to be Significantly Overvalued.
Key valuation signals for NSE:VIYASH:
Return-on-Tangible-Equity: 10.72% (near median its 10-year median of 10.31)
GF Value™: ₹172.17 vs. price of ₹277.80 (61.4% above fair value)
Industry Position: 35.7% above the Drug Manufacturers median (#316 of 901)
No single metric tells the full story. See the NSE:VIYASH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viyash Scientific Ltd is a pharmaceutical company with activities spanning formulations, active pharmaceutical ingredients (APIs), and intermediates. It is focused on research and development infrastructure for APIs and formulations. Its product portfolio spans several therapeutic areas, including ARV, cardiovascular, central nervous system, analgesics, antibiotics, antihistamines, diabetes, gastrointestinal, anticoagulants, and oncology.
76GF Score
Get the complete analysis for NSE:VIYASH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIYASH has been successfully added to your 
